ArticleAfrican journal of traditional, complementary, and alternative medicines : AJTCAM2016
SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A
Article in African journal of traditional, complementary, and alternative medicines : AJTCAM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04347382 (The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan
Who cites it
14 citing papers in PubMed, 45 citations in OpenAlex.
- The Effect of Short Treatment with Nigella Sativa on Symptoms, the Cluster of Differentiation (CD) Profile, and Inflammatory Markers in Mild COVID-19 Patients: A Randomized, Double-Blind Controlled Trial.International journal of environmental research and public health · 2022Trial
- Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial.Complementary therapies in medicine · 2021Trial
- Clinical andInfectious disorders drug targets · 2025Review
- Potential Pharmacological Applications ofPlants (Basel, Switzerland) · 2023Review
- Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral Diseases.Evidence-based complementary and alternative medicine : eCAM · 2023Review
- Identification of SARS-CoV-2 RNA-dependent RNA polymerase inhibitors from the major phytochemicals ofSaudi journal of biological sciences · 2022Article
- The Bioactivity and Phytochemicals ofAntioxidants (Basel, Switzerland) · 2021Review
- Combating COVID-19: The role of drug repurposing and medicinal plants.Journal of infection and public health · 2021Review
- Positive Therapeutic Role of Selected Foods and Plant on Ailments with a Trend Towards COVID-19: A Review.Preventive nutrition and food science · 2021Review
- Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.Drug design, development and therapy · 2021Review
- Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.Virus research · 2020Review
- A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19).Complementary therapies in clinical practice · 2020Review
- Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?Journal of pharmacopuncture · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) infection became curable because of the development of direct acting antivirals (DAAs). However, the high cost of DAAs has greatly impeded their potential impact on the treatment of HCV infection. As a result, hepatitis C will continue to cause substantial morbidity, and mortality among chronically infected individuals in low and middle income countries. Thus, urgent need exists for developing cheaper drugs available to hepatitis C patients in these countries. MATERIALS AND
methodsAlpha-zam, an indigenous herbal formulation from
resultsAlpha-zam was found to be a selective inhibitor of HCV replication. The 50% effective dilution and 50% cytotoxic dilution of Alpha-zam were 761- and < 100-fold, respectively, in the subgenomic replicon cells LucNeo#2. Its selective inhibition of HCV was also confirmed by HCV RNA levels in LucNeo#2 and in the full-genome HCV replicon cells NNC#2 using real-time reverse transcriptase polymerase chain reaction. Furthermore, the anti-HCV activity of Alpha-zam was not due to the induction of interferon.
conclusionAlpha-zam selectively inhibits HCV replication and therefore has potential for a novel antiviral agent against HCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.